Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $22.25 Consensus Price Target from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has earned an average rating of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $22.25.

A number of brokerages have weighed in on CAPR. Roth Capital reduced their price target on shares of Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating for the company in a report on Monday, July 14th. HC Wainwright reiterated a “buy” rating and issued a $24.00 target price on shares of Capricor Therapeutics in a research note on Thursday, September 25th. Alliance Global Partners reissued a “buy” rating on shares of Capricor Therapeutics in a research report on Monday, July 14th. Jones Trading cut their price target on Capricor Therapeutics from $40.00 to $29.00 and set a “buy” rating for the company in a report on Wednesday, June 25th. Finally, B. Riley started coverage on Capricor Therapeutics in a report on Thursday, June 26th. They set a “buy” rating and a $21.00 price objective on the stock.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CAPR. Tower Research Capital LLC TRC raised its stake in shares of Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 4,976 shares in the last quarter. Citizens Financial Group Inc. RI acquired a new position in Capricor Therapeutics in the first quarter worth about $95,000. ProShare Advisors LLC acquired a new position in Capricor Therapeutics in the fourth quarter worth about $142,000. KLP Kapitalforvaltning AS lifted its stake in Capricor Therapeutics by 65.2% during the second quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 4,300 shares during the period. Finally, Arizona State Retirement System acquired a new stake in Capricor Therapeutics during the first quarter valued at approximately $111,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Up 4.5%

Shares of NASDAQ:CAPR opened at $7.41 on Friday. The company has a market cap of $338.79 million, a price-to-earnings ratio of -4.52 and a beta of 0.73. The business has a 50 day moving average price of $6.95 and a 200 day moving average price of $9.26. Capricor Therapeutics has a twelve month low of $5.68 and a twelve month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%. Analysts anticipate that Capricor Therapeutics will post -1.21 EPS for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.